Back to Browse Journals » HIV/AIDS - Research and Palliative Care » Volume 3

Participation of women in HIV clinical trials: the IPEC-FIOCRUZ experience

Authors Lake JE, Friedman RK, Cunha CB, Cardoso SW, Veloso VG, Currier JS, Grinsztejn B

Published Date July 2011 Volume 2011:3 Pages 61—68

DOI http://dx.doi.org/10.2147/HIV.S18667

Published 1 July 2011

Jordan E Lake1, Ruth K Friedman2, Cynthia B Cunha2, Sandra W Cardoso2, Valdilea G Veloso2, Judith S Currier1, Beatriz Grinsztejn2
1Division of Infectious Diseases, University of California at Los Angeles, Los Angeles, CA, USA; 2Fundação Oswaldo Cruz – Instituto de Pesquisa Clínica Evandro Chagas/IPEC, Rio de Janeiro, State of Rio de Janeiro, Brazil

Background: Fifty percent of people living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) worldwide are female. In Brazil, for example, 240,000 women are infected with HIV, rates of infection in women have increased over the last two decades, and addressing HIV prevention and treatment for women at risk for, or living with, HIV/AIDS remains a challenge. To better address the needs of women living with HIV in Brazil, the Instituto de Pesquisa Clínica Evandro Chagas – Fundação Oswaldo Cruz (IPEC-FIOCRUZ) HIV Women’s Cohort was established in 1996 to study the natural history of women seeking HIV care. This analysis describes the characteristics of women in the cohort who participated in HIV clinical trials between 1999 and 2008.
Methods: A total of 736 Women’s Cohort participants were in active follow-up and 665 participants from the Women’s Cohort were included in univariable and multivariable analyses to determine socioeconomic and sociodemographic factors associated with women’s participation in HIV clinical trials at our site.
Results: Of the complete cohort, 23% participated in a clinical trial between January 1999 and July 2008. Odds of participation decreased for women who were younger than 35 years old, currently employed, had an HIV-positive sexual partner, and/or who reported a lifetime history of illicit drug use. Alternatively, the odds of participation increased for women who had more than 8 years of formal education, were living independently, and/or were married or cohabitating.
Conclusion: The rate of participation in HIV clinical trials by women in the IPEC-Fiocruz Cohort was similar to other published cohorts, but identification of local risk factors and barriers to participation remains important. Our analysis offers a novel description of the factors associated with participation in HIV clinical trials among women in care at IPEC-FIOCRUZ in Rio de Janeiro, Brazil.

Keywords: AIDS, Brazil, South America, clinical trial participation
 

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Uptake of bright fluorophore core-silica shell nanoparticles by biological systems

Zane A, McCracken C, Knight DA, Young T, Lutton AD, Olesik JW, Waldman WJ, Dutta PK

International Journal of Nanomedicine 2015, 10:1547-1567

Published Date: 20 February 2015

Layer-by-layer paper-stacking nanofibrous membranes to deliver adipose-derived stem cells for bone regeneration

Wan W, Zhang S, Ge L, Li Q, Fang X, Yuan Q, Zhong W, Ouyang J, Xing M

International Journal of Nanomedicine 2015, 10:1273-1290

Published Date: 12 February 2015

Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial

Checa MA, Brassesco M, Sastre M, Gómez M, Herrero J, Marque L, Brassesco A, Espinós JJ

International Journal of Women's Health 2015, 7:219-225

Published Date: 12 February 2015

Multifunction hexagonal liquid-crystal containing modified surface TiO2 nanoparticles and terpinen-4-ol for controlled release

Manaia EB, Kaminski RCK, Oliveira AG, CorrĂȘa MA, Chiavacci LA

International Journal of Nanomedicine 2015, 10:811-819

Published Date: 22 January 2015

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Chloronychia: green nail syndrome caused by Pseudomonas aeruginosa in elderly persons

Chiriac A, Brzezinski P, Foia L, Marincu I

Clinical Interventions in Aging 2015, 10:265-267

Published Date: 14 January 2015

Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer

Zhao XJ, Chen Q, Liu W, Li YS, Tang HB, Liu XH, Yang XL

International Journal of Nanomedicine 2015, 10:257-270

Published Date: 30 December 2014

Photothermal cancer therapy using graphitic carbon–coated magnetic particles prepared by one-pot synthesis

Lee HJ, Sanetuntikul J, Choi ES, Lee BR, Kim JH, Kim E, Shanmugam S

International Journal of Nanomedicine 2015, 10:271-282

Published Date: 30 December 2014

Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification

Lindstrom RL, Loden JC, Walters TR, Dunn SH, Whitaker JS, Kim T, Demopulos GA, Tjia K

Clinical Ophthalmology 2014, 8:1735-1744

Published Date: 5 September 2014